Alaunos Therapeutics, Inc.
TCRT
$2.63
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.44% | 0.00% | 0.00% | 66.67% | 80.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.44% | 0.00% | 0.00% | 66.67% | 80.00% |
| Cost of Revenue | 275.21% | -33.79% | -87.97% | -94.10% | -97.77% |
| Gross Profit | -283.33% | 33.94% | 88.08% | 94.20% | 97.82% |
| SG&A Expenses | -35.68% | -47.63% | -59.91% | -66.36% | -63.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.28% | -45.06% | -70.08% | -79.71% | -83.08% |
| Operating Income | 12.22% | 45.09% | 70.11% | 79.75% | 83.11% |
| Income Before Tax | 10.77% | 65.83% | 79.13% | 84.79% | 86.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.77% | 65.83% | 79.13% | 84.79% | 86.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.77% | 65.83% | 79.13% | 84.79% | 86.68% |
| EBIT | 12.22% | 45.09% | 70.11% | 79.75% | 83.11% |
| EBITDA | 12.22% | 43.25% | 67.93% | 78.03% | 81.63% |
| EPS Basic | 22.77% | 68.86% | 79.38% | 84.80% | 86.70% |
| Normalized Basic EPS | 24.33% | 48.99% | 69.92% | 80.63% | 84.08% |
| EPS Diluted | 22.77% | 68.86% | 79.38% | 84.80% | 86.70% |
| Normalized Diluted EPS | 24.33% | 48.99% | 69.92% | 80.63% | 84.08% |
| Average Basic Shares Outstanding | 21.58% | 10.27% | 1.20% | 0.04% | 0.09% |
| Average Diluted Shares Outstanding | 21.58% | 10.27% | 1.20% | 0.04% | 0.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |